Mineralys Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for cardiorenal conditions, initially uncontrolled or resistant hypertension and chronic kidney disease. The filing covers the three months ended March 31, 2024, and was filed May 9, 2024. The company has no approved products and has generated no revenue.
During the quarter, the company continued its pivotal hypertension program, including the Phase 2 Advance-HTN trial and Phase 3 Launch-HTN trial, and continued the Phase 2 Explore-CKD trial.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $30.8 million | $12.3 million | +$18.5 million |
| General and administrative expense | $4.6 million | $2.6 million | +$2.0 million |
| Total operating expenses | $35.4 million | $14.9 million | +$20.4 million |
| Interest and other income, net | $3.9 million | $2.3 million | +$1.5 million |
| Net loss | $31.5 million | $12.6 million | +$18.9 million loss |
| Basic and diluted net loss per share | $0.70 | $0.51 | Loss per share increased |
| Net cash used in operating activities | $19.1 million | $12.8 million | +$6.4 million use |
As of March 31, 2024, cash and cash equivalents were $90.4 million and investments were $248.1 million, for total cash, cash equivalents, and investments of $338.6 million. Current liabilities were $19.2 million, and the company reported no debt in the condensed balance sheet. Accumulated deficit was $156.2 million.
Operating cash use was partially offset by $116.2 million of financing cash inflows, primarily from the February 2024 private placement. Investing activities used $56.0 million, primarily reflecting purchases of marketable securities. Management expects existing cash, cash equivalents, and investments to fund operations for at least twelve months from the filing’s issuance date.
Material changes versus the prior comparable period
- Research and development expense increased primarily because of higher clinical and preclinical costs associated with the pivotal lorundrostat program and Explore-CKD, as well as higher clinical supply, manufacturing, regulatory, compensation, and stock-based compensation costs.
- General and administrative expense increased because of additional personnel and stock-based compensation, higher public-company professional fees, and increased insurance and administrative costs.
- Net loss increased to $31.5 million from $12.6 million as clinical development activities expanded.
- Interest income increased because of higher cash and investment balances and income earned on money market funds and U.S. Treasury securities.
- In February 2024, the company issued 8,339,169 common shares and pre-funded warrants for up to 549,755 additional shares, generating approximately $116.1 million of net proceeds.
- In March 2024, the company entered into an at-the-market facility permitting sales of up to $100.0 million of common stock. No ATM shares had been sold as of March 31, 2024.
- Common shares outstanding increased to 49,632,989 at March 31, 2024 from 41,133,916 at December 31, 2023, excluding potential dilution from outstanding warrants, options, and restricted awards.
Guidance, outlook, risks, contingencies, and unusual items
- Topline data from Advance-HTN is anticipated in the fourth quarter of 2024.
- Topline data from Launch-HTN is anticipated in the second half of 2025.
- Topline data from Explore-CKD is anticipated between the fourth quarter of 2024 and the first quarter of 2025.
- The company expects operating expenses and losses to increase substantially as it advances clinical trials, expands capabilities, protects intellectual property, and operates as a public company.
- Additional funding will be required. The company expects to rely on equity or debt financings, collaborations, licensing transactions, or other capital sources, but has no committed external source of funds.
- Under the Mitsubishi Tanabe license, the company has remaining potential commercial milestone obligations of up to $155.0 million, additional second-indication milestones of up to $10.0 million, and tiered royalties ranging from the mid-single digits to 10% of net sales if products are commercialized. All development milestones have been paid.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, manufacturing and supply-chain constraints, inability to raise additional capital, dilution from future financing, intellectual-property challenges, dependence on lorundrostat, and uncertainty regarding market acceptance and reimbursement.
- The company reported no material legal proceedings and no material changes to its previously disclosed risk factors.
- The CEO adopted a Rule 10b5-1 trading plan providing for sales of up to 479,389 shares, subject to vesting, from June 11, 2024 through December 31, 2025.
- Disclosure controls and procedures were assessed as effective as of March 31, 2024, with no material changes to internal control over financial reporting.
Important facts for investors to verify
- Confirm enrollment, trial execution, safety findings, and the timing and results of the Advance-HTN, Launch-HTN, and Explore-CKD programs.
- Assess the company’s cash runway against the pace of quarterly operating cash burn and anticipated clinical-development spending.
- Monitor whether the $100.0 million ATM facility is used and the resulting dilution to existing shareholders.
- Review outstanding pre-funded warrants, options, restricted stock awards, and other potential common-share dilution.
- Evaluate future financing needs and the availability and terms of potential equity, debt, or strategic funding.
- Review the Mitsubishi Tanabe license for commercial milestones, royalty obligations, termination provisions, and development commitments.
- Verify that the company remains without product revenue and that regulatory approval and commercialization remain several years away, if achievable.